Silo Pharma, Inc.
SILO
$0.63
-$0.011-1.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | 1.69% | 1.69% | -1.67% | -1.67% | -1.67% |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | -20.77% | -19.80% | -23.86% | -20.08% | 10.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.69% | 21.64% | -8.40% | -16.89% | -1.43% |
| Operating Income | -25.15% | -22.05% | 8.54% | 17.16% | 1.46% |
| Income Before Tax | -31.08% | -20.98% | 12.46% | 24.53% | 16.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.08% | -20.98% | 12.46% | 24.53% | 16.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.54% | -18.70% | 10.82% | 23.01% | 14.60% |
| EBIT | -25.15% | -22.05% | 8.54% | 17.16% | 1.46% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 4.77% | 1.22% | 12.15% | 27.47% | 26.93% |
| Normalized Basic EPS | 2.71% | -5.55% | 10.41% | 25.79% | 21.27% |
| EPS Diluted | 4.77% | 1.22% | 12.15% | 27.47% | 26.93% |
| Normalized Diluted EPS | 2.71% | -5.55% | 10.41% | 25.79% | 21.27% |
| Average Basic Shares Outstanding | 33.74% | 17.68% | 5.59% | 5.39% | 18.28% |
| Average Diluted Shares Outstanding | 33.74% | 17.68% | 5.59% | 5.39% | 18.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |